ReviewTrialReported positiveModerate evidenceTier 4 · clinical
Drugs · Jul 2021 · review article summarizing drug development and approval
Fuzuloparibovarian cancerfallopian tube cancerprimary peritoneal cancersolid cancerspancreatic cancerbreast cancerprostate cancerlung cancer This review describes fuzuloparib, an oral PARP inhibitor, and its development leading to approval in China. The approval was for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with a germline BRCA mutation after second-line or later chemotherapy. The abstract also notes that phase II and III trials are ongoing in other solid cancers.
Key findings
- Fuzuloparib is an orally active PARP inhibitor.
- It has been approved in China for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with germline BRCA mutation after second-line or above chemotherapy.
- Phase II and III trials are investigating it in other solid cancers.
Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..
This is a drug approval review focused on fuzuloparib's use in ovarian and related cancers, not an experimental efficacy study.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical
Cells · Sep 2020 · review
medulloblastomarhabdomyosarcomabasal cell carcinomaglioblastomalung cancercolon cancerstomach cancerpancreatic cancerovarian cancerbreast cancer
This article is a narrative review of the Hedgehog (HH) signaling pathway and its role in human cancers. The authors summarize how aberrant HH signaling contributes to tumorigenesis, aggressive tumor phenotypes (including progression, metastasis, and drug resistance), and describe alternative splicing of GLI1 that produces a tumor-specific, gain-of-function truncated isoform (tGLI1). The review highlights GLI1 and SMO as components under investigation as therapeutic targets.
Key findings
- Hedgehog signaling regulates normal cell growth and differentiation and, when aberrantly activated, contributes to tumorigenesis and aggressive cancer phenotypes.
- Canonical HH activation involves HH ligands binding PTCH1, derepression of SMO, release of GLI1 from SUFU, nuclear translocation, and activation of target genes.
- GLI1 transcripts undergo alternative splicing producing variants including a loss-of-function GLI1ΔN and a tumor-specific gain-of-function truncated GLI1 (tGLI1).
- Aberrant HH activation has been implicated in multiple cancer types (medulloblastoma, rhabdomyosarcoma, basal cell carcinoma, glioblastoma, and cancers of lung, colon, stomach, pancreas, ovary, and breast).
- Several components of the HH pathway, particularly GLI1 and SMO, are under investigation as targets for cancer-directed therapies.
Limitations: Narrative review article; no new primary experimental or clinical data are reported in this paper.; Abstract does not indicate systematic review methods or quantitative synthesis, so selection and summary bias are possible.; No quantitative outcomes, effect sizes, or clinical trial results are provided in the abstract.; Broad summary across many cancer types without cancer-specific experimental details in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text